[skissane]

> But there's no profit in prevention

Drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are making massive profits, and also have decent odds of preventing many obesity-induced (and also diabetes-induced) diseases

Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to

And even if some of those drugs turn out to have unacceptable side effects in the long-run, there are other drugs in that class in the pipeline which might avoid those side effects, in which case the profits will shift to those

[JamesBarney]

> Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to

This is very unlikely to happen. This isn't like other obesity drugs that were first in class, glp-1 agonists have been around a long time and have a great safety record.